Navigantis has announced the first successful neurovascular clinical cases performed with its Vasco interventional robotic platform for patients suffering from neurovascular disorders.
“This achievement marks an important milestone in our mission to introduce the advantages of robotic procedures to the interventional neurovascular field,” said Mor Dayan, chief executive officer (CEO) of Navigantis. “The Vasco robotic platform has the potential to redefine how we approach the most complex and time-sensitive neurovascular procedures, ultimately improving both patient outcomes and procedural efficiencies. This is one of the first steps towards enabling robotic telesurgery for stroke patients, which could dramatically reduce response times and enhance access to timely critical care.”
This neurovascular interventional robotic clinical trial includes patients undergoing diagnostic cerebral angiograms, brain tumour embolisations, and mechanical thrombectomies for ischaemic stroke, according to Navigantis. The study is being led by Dong Joon Kim (Severance Hospital, Seoul, South Korea)—a pioneer in the robotic neurointerventional space.
“These first successful robotic cases are a major stepping stone towards treating more complex neurovascular diseases,” Kim said.
A company press release states that this update builds on Navigantis’ first-in-human (FIH) study from 2022, during which Vasco’s previous generation was successfully used to perform robotic embolisation of liver tumours.
